Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market
Overview:
An autologous stem cell transplant uses healthy blood stem cells from the own body to replace the diseased or damaged bone marrow. It is the process of transplantation in which stem cells or undifferentiated cells are taken from an individual, accumulated, and later given back to the same individual later. It is performed through hematopoietic stem cells in hematopoietic stem cell transplantation, in some cases heart cells are used productively to repair damage caused by a heart attack. There are two types of stem cell transplantation, including allogenic stem cell transplantation and autologous stem-cell transplantation. In an allogeneic transplant, a person’s stem cells are replaced with new, healthy stem cells. The new cells come from a donor or from donated umbilical cord blood. An immediate family member, brother or sister, is the best donor in allogeneic stem cell transplantation. If not found in the family, the donor can be found from the public. This is often called a matched unrelated donor (MUD) transplant.
To Get more information Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/523
Drivers:
Increasing prevalence of cancer and diabetes around the world is expected to boost the growth of the global autologous stem cell and non-stem cell based therapies market during the forecast period. For instance, as per the World Health Organization (WHO), the prevalence of diabetes has increased from 108 million in 1980 to 422 million in 2014. Moreover, cancer was one of the leading cause of death around the world, accounting for around 9.6 million deaths in 2018.
Furthermore, growing geriatric population across the globe is expected to drive growth of the global autologous stem cell and non-stem cell based therapies market. For instance, according to the 2019 Revision of World Population Prospects, the number of people aged 80 years and over is increasing rapidly worldwide, and the number is expected to be triple from 143 million in 2019 to 426 million in 2050.
Restraints:
Risks/complications associated with treatment or side effects, such as nausea, vomiting, hair loss, diarrhea, severe infections, heart problems, and infertility, are expected to hinder growth of the global autologous stem cell and non-stem cell based therapies market.
Market Taxonomy:
By Application:
- Neurodegenerative diseases
- Cardiovascular diseases
- Cancer and autoimmune diseases
- Skin transplantation
- Infectious disease
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/523
Regional Insights:
North America is expected to witness significant growth in the global autologous stem cell and non-stem cell based therapies market due to the increasing prevalence of cancer in the region. For instance, according to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancer will be diagnosed in the United States and 595,690 people will die from the disease. Thus, with the increase in prevalence of cancer, the demand for autologous stem cell and non-stem cell based therapies in also increasing with a rapid pace.
Moreover, Europe is expected to witness robust growth in the global autologous stem cell and non-stem cell based therapies market owing to the increasing prevalence of infectious diseases, increasing demand for these therapies, and minimization of risks related with these treatments.
Furthermore, Asia Pacific is also expected to witness robust growth in the market owing to the high prevalence of cardiovascular diseases, increasing demand for these therapies, and well-established healthcare infrastructure, especially in India, China, Vietnam, and Malaysia.
Competitive Landscape:
Key players active in the global autologous stem cell and non-stem cell based therapies market are Caladrius Biosciences, Fibrocell Science, Inc., Vericel Corporation, Genzyme Corporation, Dendreon Corporation, Regeneus Ltd., and BrainStorm Cell Therapeutics.
Key Developments:
In November 2019, Caladrius Biosciences announced positive results of CD34+ cell therapy CLBS16 from the ESCaPE-CMD Trial as a significant advancement in treatment of Coronary Microvascular Dysfunction (CMD), a condition that disproportionately afflicts women.
In February 2018, MEDIPOST received the Food and Drug Administration (FDA) approval for NEUROSTEM, its stem cell-based Alzheimer’s disease drug, for clinical trials.
Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/523
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Impact
Chapter 2 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Competition by Types, Applications, and Top Regions and Countries
2.1 Autologous Stem Cell and Non-Stem Cell Based Therapies Market (Volume and Value) by Type
2.3 Autologous Stem Cell and Non-Stem Cell Based Therapies Market (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Sales, Consumption, Export, Import by Regions
Chapter 5 North America Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Analysis
Chapter 6 East Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Analysis
Chapter 7 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Analysis
Chapter 8 South Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Analysis
Chapter 9 Southeast Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Analysis
Chapter 10 Middle East Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Analysis
Chapter 11 Africa Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Analysis
Chapter 12 Oceania Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Analysis
Chapter 13 South America Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Analysis
Chapter 14 Company Profiles and Key Figures in Autologous Stem Cell and Non-Stem Cell Based Therapies Market Business
Chapter 15 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Market Forecast (2021-2028)
Chapter 16 Conclusions
Research Methodology….
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837